

HEMACARE CORP /CA/  
Form 8-K  
March 31, 2005

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 24, 2005**

**HEMACARE CORPORATION**

(Exact name of registrant as specified in its charter)

**California**  
(State or other jurisdiction  
of incorporation or organization)

**000-15223**  
(Commission File Number)

**95-3280412**  
(I.R.S. Employer Identification No.)

**21101 Oxnard Street, Woodland Hills, CA 91367**

(Address of principal executive offices) (Zip Code)

Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

(Registrant's telephone number, including area code): **818-226-1968**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 2.02 Results of Operations and Financial Condition**

On March 24, 2005, HemaCare Corporation issued a press release announcing financial results for the fourth quarter and full year of 2004. A copy is attached as Exhibit 99.1 to this report and is incorporated herein by reference.

On March 24, 2005, HemaCare Corporation held an investor conference call discussing the financial results for the fourth quarter and full year of 2004. A transcript, of the conference call is attached to this report as Exhibit 99.2 and is incorporated herein by reference.

The information in this Current Report on Form 8-K, including the exhibits, will not be treated as filed for the purposes of Section 18 of the Securities and Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report. The furnishing of the information in this Current Report is not intended to, and does not, constitute a representation that such furnishing is required by Regulation FD or that the information this Current Report contains is material investor information that is not otherwise publicly available.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated March 24, 2005
99.2	Transcript of the conference call conducted by HemaCare Corporation on March 24, 2005

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 25, 2005

**HEMACARE CORPORATION**

By: /s/ Robert S. Chilton

Robert S. Chilton  
Chief Financial Officer



**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated March 24, 2005
99.2	Transcript of the conference call conducted by HemaCare Corporation on March 24, 2005